Mesoblast Limited (ASX:MSB) revealed that the Company commenced enrollment for a Phase 2/3 randomized, placebo-controlled trial to rigorously confirm whether remestemcel-L (allogeneic mesenchymal stem cell therapy) provides a survival benefit in moderate/severe acute respiratory distress syndrome (ARDS) due to COVID-19.
Mesoblast unveiled that more than 20 medical centers across the US shall take part in the trial, and it is projected to complete enrollment within 3-4 months.
Shares of MSB climbed 4.1% to $3.290 on 30 April 2020 (at AEST 11:42 AM)
Disclaimer
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.
